ABVX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Abivax SA (ABVX) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has promising clinical developments and positive long-term potential, the recent price decline, cautious analyst sentiment, and lack of immediate strong trading signals suggest holding off for now. The investor may consider revisiting the stock closer to Q2 2026 when more data is expected.
The stock's MACD histogram is positive but contracting, indicating weakening bullish momentum. RSI is neutral at 32.204, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading near its key support level (S1: 119.096), suggesting limited immediate upside potential.
Abivax presented promising clinical findings on obefazimod at the ECCO Congress, highlighting its anti-fibrotic potential and favorable safety profile. Analysts have raised price targets in the past months, citing strong Phase 3 data and potential market impact.
Wedbush initiated coverage with an Underperform rating and a $110 price target, citing caution around M&A speculation and recommending waiting for Q2 data. The stock has declined 3.13% in regular trading, reflecting potential short-term weakness.
No financial data available for analysis.
Mixed sentiment from analysts. Recent upgrades from Morgan Stanley, BTIG, and Guggenheim highlight optimism around clinical progress and market potential, with price targets ranging from $131 to $175. However, Wedbush's Underperform rating and $110 price target reflect caution on near-term risks.
